{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-005649","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.388479+00:00","generated_at":"2026-06-06T05:06:40.307949+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AIM ImmunoTech reports positive Phase 2 topline results for Ampligen in post-COVID fatigue","bullets":["Primary endpoint (PROMIS Fatigue Score at week 13) not significant; Ampligen showed lower fatigue at multiple timepoints vs placebo.","Secondary and ad hoc analyses showed differences in PROMIS Fatigue Score reaching or approaching statistical significance at several timepoints.","Six-Minute Walk Test: Ampligen group had higher distance traveled at week 13 vs placebo.","Safety: Ampligen generally well tolerated; no severe TEAEs or deaths. 15% mild treatment-related TEAEs in Ampligen group.","Study enrolled 80 subjects (40 per arm); 82.5% completed (90% Ampligen, 75% placebo)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-005649","json":"https://secwatch.observer/filing/0001493152-24-005649.json","markdown":"https://secwatch.observer/filing/0001493152-24-005649.md","text":"https://secwatch.observer/filing/0001493152-24-005649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315224005649/0001493152-24-005649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315224005649/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:06:40.307949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}